Dong-A ST and National Clinical Trial Support Foundation Sign Business Agreement for Domestic Introduction of Globally Unintroduced Drugs

At the signing ceremony of the business agreement between Dong-A ST and the National Clinical Trial Support Foundation for the domestic introduction of global non-introduced drugs, Kim Min-young, President of Dong-A ST (right), and Bae Byung-jun, Chairman of the National Clinical Trial Support Foundation, are posing for a commemorative photo.
[Photo by Dong-A ST]

[Asia Economy Reporter Lee Gwanju] Dong-A ST announced on the 6th that it has signed a business agreement with the National Clinical Trial Support Foundation to introduce global unintroduced drugs into Korea.

This agreement was prepared to contribute to the improvement of public health by resolving unmet medical needs in Korea and expanding treatment opportunities for patients with rare and intractable diseases.

According to the agreement, Dong-A ST and the National Clinical Trial Support Foundation plan to share information on new drugs that have been developed and marketed overseas but not introduced domestically, and to continue mutual cooperation necessary for their introduction.

The National Clinical Trial Support Foundation will share with Dong-A ST the results of the "Domestic Introduction Plan for Global New Drugs Not Introduced in Korea," derived based on advice from expert groups. Based on this, Dong-A ST and the National Clinical Trial Support Foundation will cooperate to introduce 244 types of new drugs not yet introduced in Korea.

Bae Byungjun, Chairman of the National Clinical Trial Support Foundation, said, “This agreement is significant as a new form of cooperation between public institutions and private companies for the introduction of overseas new drugs,” and added, “We will work with Dong-A ST to prepare practical alternatives to improve treatment accessibility for domestic patients.”

Kim Minyoung, CEO of Dong-A ST, said, “Through this agreement, I hope to help introduce overseas new drugs early and alleviate the suffering of patients and their families who suffer from rare and intractable diseases.”

This content was produced with the assistance of AI translation services.